TIDMMPH
Mereo BioPharma Group plc
23 November 2020
Mereo BioPharma Appoints Suba Krishnan, M.D. Senior Vice
President of Clinical Development
London and Redwood City, Calif., November 23, 2020 - Mereo
BioPharma Group plc (NASDAQ: MREO, AIM: MPH) ("Mereo" or "the
Company"), a clinical stage biopharmaceutical company focused on
oncology and rare diseases, today announces the appointment of Suba
Krishnan, M.D. as Senior Vice President of Clinical Development,
effective December 7, 2020. Dr. Krishnan joins Mereo with more than
20 years of experience, encompassing early and late stage
immuno-oncology drug development, academia and clinical
practice.
Dr. Denise Scots-Knight, Chief Executive Officer of Mereo
commented, "We are thrilled to have Dr. Krishnan join Mereo as SVP
of Clinical Development. Having spent the past 10 years in
immuno-oncology in the solid tumor space, we believe that her
experience will prove invaluable as we continue to progress
etigilimab through the clinic. Under Dr. Krishnan's leadership, we
believe that Mereo is well positioned to continue advancing the
etigilimab program."
Dr. Krishnan joins Mereo from Genmab, where she was the Global
Program Head of Immuno-Oncology, overseeing clinical strategy and
development of the Company's solid tumor immuno-oncology programs.
Prior to Genmab, Dr. Krishnan was a senior principal scientist at
Merck, where she served as the clinical lead for Merck's Phase 2
Lynparza monotherapy basket study in HRRm-HRD positive advanced
solid tumors. Previously, Dr. Krishnan held clinical leadership
roles at MedImmune, Bristol-Myers Squibb, Shire and Sangart, where
she worked on multiple novel immuno-oncology candidates as well as
hematology programs. At Bristol-Myers Squibb Suba was Clinical Lead
on multiple Phase 2 and Phase 3 studies for Nivolumab including the
Phase 3 and registration in second line metastatic bladder
cancer.
In addition to her industry work, Dr. Krishnan has also spent
over 10 years in academia, most recently as Assistant Professor,
Division of Pediatric Hematology Research at the Thomas Jefferson
University in Philadelphia, PA. She has authored or co-authored
numerous publications in various peer-reviewed journals and had
more than 20 poster presentations and abstracts accepted to major
medical conferences including ASCO, SITC, ASH and ESMO. Dr.
Krishnan completed her Bachelor of Medicine and Bachelor of Surgery
at the Armed Forces Medical College, Pune University in Pune,
India, and completed fellowship training in Pediatric
Hematology/Oncology at Columbia University, New York and conducted
post-doctoral research at Weill Medical College of Cornell
University.
"The etigilimab data presented to-date have been highly
compelling," commented Dr. Krishnan. "I am honored to join Mereo at
such an important stage in the development of etigilimab. I look
forward to helping the Company continue to advance this promising
anti-TIGIT therapeutic candidate, and to supporting the development
of other potentially life-saving therapies."
About Mereo BioPharma
Mereo BioPharma is a biopharmaceutical company focused on the
development and commercialization of innovative therapeutics that
aim to improve outcomes for oncology and rare diseases. Mereo's
lead oncology product candidate, etigilimab (Anti-TIGIT), has
completed a Phase 1a dose escalation clinical trial in patients
with advanced solid tumors and has been evaluated in a Phase 1b
study in combination with nivolumab in select tumor types. The
company recently announced initiation of a Phase 1b/2 study of
etigilimab in combination with an anti-PD-1/PDL-1 in a range of
different tumor types. Mereo's rare disease product portfolio
consists of setrusumab, which has completed a Phase 2b dose-ranging
study in adults with osteogenesis imperfecta (OI), as well as
alvelestat, which is being investigated in a Phase 2
proof-of-concept clinical trial in patients with alpha-1
antitrypsin deficiency (AATD) and in a Phase 1b/2 clinical trial in
COVID-19 respiratory disease.
Forward-Looking Statements
This Announcement contains "forward-looking statements." All
statements other than statements of historical fact contained in
this Announcement are forward-looking statements within the meaning
of Section 27A of the United States Securities Act of 1933, as
amended and Section 21E of the United States Securities Exchange
Act of 1934, as amended. Forward-looking statements usually relate
to future events and anticipated revenues, earnings, cash flows or
other aspects of our operations or operating results.
Forward-looking statements are often identified by the words
"believe," "expect," "anticipate," "plan," "intend," "foresee,"
"should," "would," "could," "may," "estimate," "outlook" and
similar expressions, including the negative thereof. The absence of
these words, however, does not mean that the statements are not
forward-looking. These forward-looking statements are based on the
Company's current expectations, beliefs and assumptions concerning
future developments and business conditions and their potential
effect on the Company. While management believes that these
forward-looking statements are reasonable as and when made, there
can be no assurance that future developments affecting the Company
will be those that it anticipates.
All of the Company's forward-looking statements involve known
and unknown risks and uncertainties some of which are significant
or beyond its control and involve assumptions that could cause
actual results to differ materially from the Company's historical
experience and its present expectations or projections.
These forward-looking statements are subject to risks and
uncertainties, including, among other things, those described in
the Company's latest Annual Report on Form 20-F, Reports on Form
6-K and other documents filed from time to time by the Company with
the United States Securities and Exchange Commission. The Company
wishes to caution investors not to place undue reliance on any
forward-looking statements, which speak only as of the date hereof.
The Company undertakes no obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise, except to the extent
required by law.
Mereo BioPharma Contacts:
Mereo +44 (0)333 023 7300
Denise Scots-Knight, Chief Executive Officer
N+1 Singer (Nominated Adviser and Broker
to Mereo) +44 (0)20 7496 3081
Phil Davies
Will Goode
Burns McClellan (US Investor Relations
Adviser to Mereo) +01 212 213 0006
Lisa Burns
Lee Roth
FTI Consulting (UK Public Relations Adviser
to Mereo) +44 (0)20 3727 1000
Simon Conway
Ciara Martin
Investors investors@mereobiopharma.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAKZMZMLZDGGZM
(END) Dow Jones Newswires
November 23, 2020 07:00 ET (12:00 GMT)
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From Nov 2024 to Dec 2024
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From Dec 2023 to Dec 2024
